Prerpints.org logo
Preprint
Review

Flavonoids As CYP3A4 Inhibitors In Vitro

Altmetrics

Downloads

146

Views

47

Comments

0

A peer-reviewed article of this preprint also exists.

This version is not peer-reviewed

Submitted:

09 January 2024

Posted:

10 January 2024

You are already at the latest version

Alerts
Abstract
Flavonoids, a diverse group of polyphenolic compounds found abundantly in fruits, vegetables, and beverages like tea and wine, offer a plethora of health benefits. However, their potential interaction with drug metabolism, particularly through inhibition of the cytochrome P450 3A4 enzyme, the most versatile and abundant enzyme in the liver. CYP3A4 is responsible for metabolizing approximately 50% of clinically prescribed drugs across diverse therapeutic classes, so these interactions have raised concerns about potential adverse effects. This review delves into the scientific evidence surrounding flavonoid-mediated CYP3A4 inhibition, exploring the inhibitory potential of investigated flavonoids and future implications. Kusehnol I, chrysin, leachianone A and sophoraflavone G showed the largest inhibitory potentials and lowest IC50 values. While the clinical significance of flavonoid-mediated CYP3A4 inhibition in dietary contexts is generally considered low due to moderate intake and complex interactions, it poses a potential concern for individuals consuming high doses of flavonoid supplements or concurrently taking medications metabolized by CYP3A4. This can lead to increased drug exposure, potentially triggering adverse reactions or reduced efficacy.
Keywords: 
Subject: Medicine and Pharmacology  -   Pharmacy

1. Introduction

Dietary supplements based on natural ingredients are often used to support general health and well-being, but it is important to be aware of potential interactions with medications. Natural ingredients in dietary supplements can influence the metabolism and absorption of drugs, leading to changes in the effectiveness or safety of prescribed therapy [1]. Certain herbal extracts may potentially enhance or diminish the effects of specific medications causing multiple clinical manifestations and adverse events [2,3,4]. Individual variations in metabolism and health status also play a role in these interactions, so it is important to monitor adverse drug reactions (ADRs), because dietary supplements, often derived from plants and other natural sources, may contain active compounds that can interact with prescription medications. These interactions can lead to a range of ADRs, including reduced drug efficacy, increased drug toxicity, or even life-threatening conditions [5]. Understanding these interactions can help healthcare providers and patients make informed decisions about the use of supplements alongside medications.
Certain dietary supplements may enhance the effectiveness of certain medications, potentially leading to improved treatment outcomes. For instance, certain flavonoids, found in fruits and vegetables, can enhance the absorption and bioavailability of certain antibiotics [6,7,8,9,10]. Conversely, supplements may interfere with the metabolism of medications, reducing their effectiveness or increasing their side effects. By understanding the potential interactions between supplements and medications, healthcare providers can tailor treatment plans to minimize the risk of ADRs and optimize the efficacy of both supplements and medications. This can lead to improved patient outcomes and overall health. Patients, on the other hand, should be aware of the potential interactions between supplements and medications they are taking. By providing clear information about these interactions, healthcare providers can empower patients to make informed decisions about their healthcare and avoid potential risks.
Thoroughly understanding supplement-medication interactions is essential for safeguarding public health. By identifying and preventing potential ADRs, healthcare professionals can protect patients from harm and ensure the safe and effective use of both supplements and medications. By understanding the potential interactions between supplements and medications, healthcare providers can tailor treatment plans to minimize the risk of ADRs and optimize the efficacy of both supplements and medications. This can lead to improved patient outcomes and overall health. The intricate interplay of hepatic cytochrome P450 (CYP) enzymes plays a significant role in modulating the pharmacokinetics of administered medications. Co-administration of certain drugs can induce or inhibit the activity of these enzymes, leading to alterations in the metabolism and bioavailability of other drugs. Notably, enzyme inhibition is a more prevalent phenomenon than induction [11]. Therefore, comprehending the mechanisms underlying enzyme inhibition and induction is crucial for optimizing the efficacy and safety of multi-drug therapies.
In order to determine the clinical significance and therapeutic manifestation of interactions between flavonoids and cytochrome P450 3A4 (CYP3A4) enzymes, the aim of this work was to provide an overview of current knowledge in the field of inhibition of CYP3A4 enzymes by different groups of flavonoids. The review paper was made by searching the PubMed database for papers published with the keywords “CYP3A4; flavonoid; inhibition; in vitro” for the period until October 1st, 2023. The search resulted in 343 papers. After the initial analysis and proof-reading of abstracts, 87 papers were selected for further analysis. After reading and analyzing the papers, 29 papers were selected for research. The inclusion criteria were that the paper was open access, had to provide a specific flavonoid, flavonoid derivate or flavonoid conjugate and had to provide in vitro inhibition details on CYP3A4 in form of IC50 and/or enzyme residual activity. A total of 86 flavonoids and their inhibitory potential towards CYP3A4 were explored. To the knowledge of the authors this represents the biggest review of flavonoids and CYP3A4 inhibition.

2. CYP enzymes

CYP enzymes are a group of heme-containing enzymes that play important roles in the metabolism of many drugs and other xenobiotics. They are located in the endoplasmic reticulum of cells throughout the body, but they are most abundant in the liver [12]. CYP enzymes can catalyze a wide variety of reactions, including oxidation [13], reduction [14], hydrolysis [15], and isomerization [16]. The most common reaction catalyzed by CYP enzymes is oxidation. This leads to the molecule being more water-soluble and easier to excrete from the body, but it can also make it more reactive and potentially toxic. Moreover, CYPs are involved in more than 90% of the reported enzymatic reactions [14].
CYP enzymes contain between 400 and 500 amino acid residues and one heme prosthetic group in the active site, iron in protoporphyrin IX [17]. In this structure, four pyrrole rings (I-IV) are interconnected by methyl bridges α, β, γ and δ. Iron in trivalent (ferric, Fe3+) form is located in the center of the protoporphyrin ring (Figure 1) and is coordinated by pyrrolic nitrogen. In addition, a water molecule is bound to the iron in the native structure. The heme iron is bound to the apoprotein via the thiol group of the cysteine ​​residue. These are also the places for potential CYP inactivation by a covalent heme modification, by the modification of the apoprotein or by forming a pseudo-irreversible complex with iron [18].
CYP enzymes are part of a superfamily of enzymes that is further divided into 18 families, 43 subfamilies and at least 57 different enzymes present in humans [15]. The division of the nomenclature of CYP enzymes is based on the similarity of their primary structure, or protein sequence [17], as shown in Table 1. The enzymes are encoded by a family of genes in the CYP superfamily. The specific CYP enzymes that are expressed in a particular cell or tissue depend on the genes that are present in that cell or tissue.
The role of these enzymes in the body is versatile. As mentioned earlier, these enzymes are not only present in the liver, but also in the kidney, placenta, adrenal gland, gastrointestinal tract, and skin [19]. Thanks to their distribution throughout the body and the possibility of catalyzing a large number of different chemical reactions, CYP enzymes are responsible, among other things, for drug metabolism, steroid metabolism, bile acid biosynthesis, steroid biosynthesis, vitamin D deactivation and much more [15]. This role of theirs extends doubly to their functions in human health and disease. CYP enzymes are responsible for numerous protective roles in the biotransformation of toxins and other harmful substances, but also in causing side effects and toxic elements through unproductive cycles of CYP enzymes [20].
An additional aspect of the importance of CYP enzymes lies in their role in antitumor therapy. CYP enzymes have been detected in tumor cells [21,22], where their expression is abnormal compared to the surrounding healthy tissue [23]. Accordingly, experts are actively working to use the CYP enzyme as a target in modeling oncology therapy, with CYP1B1 [24], CYP2J2 [25], and CYP2W1 [26] being extensively studied. The study of CYP enzymes is an important area of ​​research in pharmacology, toxicology, and cancer biology. Understanding how CYP enzymes work can help design more effective and less toxic drugs and develop strategies for cancer prevention and treatment.

2.1. CYP3A4 enzyme

CYP3A4 is one of the most important enzymes involved in drug metabolism. It is encoded by the CYP3A4 gene, located on chromosome 7q at the q21-22 locus, but variations in the coding of this gene are also responsible for variations in the presence of the CYP3A4 enzyme in humans [27]. It is not present in the fetus, but in most people, it is formed within a year of birth [28]. CYP3A4 is distributed in different tissues, but the highest presence of this enzyme, as well as the highest significance, was observed in the liver and intestine [29] and is responsible for more than 70% of gastrointestinal CYP activity [30]. CYP enzymes in the body catalyze more than 95% of oxidation and reduction reactions, while the CYP3A4 enzyme is responsible for catalyzing approximately 33% of such reactions [31]. It is believed that the large active site of this enzyme is responsible for participating in a large number of chemical reactions, and consequently also in a large number of drug bio-transformations. The CYP3A4 enzyme is mentioned as the most important enzyme in drug metabolism, where it is considered to be involved in the metabolism of more than 50% of drugs [32]. Therefore, it is extremely important to know all the possible characteristics of this enzyme, especially the significantly present polymorphism of this enzyme. The rate of CYP3A4 metabolism can vary between individuals. This is a consequence of genetic polymorphisms, which can cause the enzyme to be more or less active. People with certain CYP3A4 polymorphisms may have a different rate of drug metabolism than people without these polymorphisms. For example, people with the CYP3A4*2C9 polymorphism have a higher risk of side effects from statins, which are metabolized by CYP3A4 [33]. In addition to drug dose adjustments, knowledge of CYP3A4 polymorphisms can help physicians identify people who are at higher risk of side effects. Some drugs can cause side effects if they are metabolized too quickly or too slowly. It is believed that there is 1 to 20-fold interindividual 'variability' of enzyme activity [30]. The levels of CYP3A4 in humans remain the same with increasing age, it is not influenced by external factors such as smoking or alcohol and is 25% more present in females [34].
When the CYP3A4 enzyme is mentioned, the CYP3A5 enzyme is often mentioned in the same context, since it is an enzyme that is highly homologous and has overlapping substrates. Therefore, the term CYP3A4/5 enzyme is often used in the literature. However, it is important to emphasize that these two enzymes have different functions in some cases. For example, in the process of O6-demethylation of thebaine, CYP3A5 isoform participates almost ten times more than CYP3A4 [35]. The reaction marker for measuring CYP3A4 enzyme activity is the 6β-hydroxylation of testosterone. Nifedipine oxidation is used as well in order to further confirm the activity of the enzyme [17]. It has already been said that the CYP3A4 enzyme is involved in numerous chemical reactions (hydroxylation, aromatic oxidation, N- and O-dealkylation...). Due to its large active site, it is able to both bind several substrates at once and create more complex metabolites through hydroxylation of the sp3 bond between carbon and hydrogen [36].
Many xenobiotics and endobiotics can act as CYP3A4 inducers, substrates, or inhibitors. The induction of CYP3A4 is less clinically significant than CYP3A4 inhibition but is necessary to understand because it can lead to decreased systematic exposure of co-administered drugs and result in inadequate therapeutic values of certain medications [37]. CYP3A4 induction occurs primarily at the transcriptional level, which involves the activation of the CYP3A4 gene promoter, the region of DNA that regulates gene expression. Two major nuclear receptors, pregnane X receptor (PXR) and constitutive androstane receptor (CAR), are primarily responsible for CYP3A4 induction [38]. These receptors act as transcription factors, which means they bind to specific DNA sequences and recruit RNA polymerase, the enzyme responsible for DNA transcription. PXR is activated by a variety of compounds, including endogenous ligands such as bile acids and xenobiotics such as certain drugs, environmental pollutants, and pesticides. Upon binding to PXR, these ligands induce its translocation from the cytoplasm to the nucleus, where it binds to its heterodimeric partner, retinoid X receptor (RXRα), and interacts with specific DNA sequences in the CYP3A4 gene promoter [39]. This interaction enhances the binding of RNA polymerase, leading to increased transcription of the CYP3A4 gene and increased CYP3A4 protein expression. While previous models have assumed that enzyme induction is a rapid process driven by immediate changes in enzyme synthesis, more recent studies suggest that the induction response may be more complex and involve a lag phase before full induction is achieved. This delayed response could be attributed to the slower kinetics of mRNA synthesis, which may take several days to reach peak levels [40,41]. Some of the inducers of CYP3A4 include but are not limited to [42,43,44,45,46,47,48]: apalutamide, capsaicin, carbamazepine, efavirenz, enzalutamide, modafinil, nevirapine, phenobarbital, phenytoin, rifampicin, St. John's wort and topiramate. Some of the substrates on the other hand include [49,50,51,52,53,54,55,56]: aripiprazole, clarithromycin, cyclophosphamide, cyclosporin, doxorubicin, erythromycin, haloperidol, ifosfamide, ketoconazole, losartan, paclitaxel, sunitinib, tacrolimus, tamoxifen, verapamil, vincristine, and many others.

2.2. CYP3A4 inhibitors

Probably the most important item in the study of interactions of CYP enzymes with endobiotics and xenobiotics is the process of inhibition of CYP enzymes. Inhibitors are compounds that can bind to the active site or prevent the enzyme from catalyzing chemical reactions. In some cases, inhibitors can do both and thus lead to a decrease in enzyme activity. A decrease in enzyme activity will consequently lead to a decrease in the biotransformation of substrates, in some cases of drugs, and may lead to an increased concentration of drugs in the blood system. Because of this, but also because of the influence on the development of new drugs, the processes of inhibition of various types of enzymes, including the CYP3A4 enzyme, are significantly studied. One of the most common criteria used to determine inhibitor strength is the 50% inhibitory concentration (IC50). The IC50 value determines half of the maximum inhibitory concentration; a measure of the strength by which a certain compound can inhibit a biological or biochemical function [57]. IC50 values ​​are usually calculated using kinetic methods. One of the most common methods is the inhibition quadrant method. In this method, the enzyme is incubated with different concentrations of inhibitors and the reaction rate is measured. The IC50 value is then determined from the graph of the reaction rate in relation to the concentration of the inhibitor. A lower IC50 value indicates a higher potency of the inhibitor. This means that a lower inhibitor concentration is required to achieve 50% inhibitory inactivation of the enzyme. According to the current literature guidelines on this topic, inhibitors are divided into strong, medium, and weak. Strong inhibitors are those that show an IC50 value at a concentration of less than 1 μM, medium inhibitors are those that show an IC50 value from 1 μM to 50 μM, and weak inhibitors are those that show an IC50 value greater than 50 μM [58,59].
When CYP3A4 enzyme inhibition is mentioned, it should be kept in mind that there are significantly different types of inhibition, and therefore different clinical implications (Figure 2). CYP3A4 enzymes can be subject to reversible inhibition in which the enzyme is bound by non-covalent bonds, which allows it to be easily removed from the enzyme and return to enzymatic activity. An example of a reversible inhibitor of the CYP3A4 enzyme is ketoconazole [60], which shows different types of inhibition – competitive and non-competitive inhibition. The third subtype of reversible inhibition, uncompetitive inhibition, is not a common case for CYP3A4 enzymes and is mentioned only sporadically [61]. A much more significant type of CYP3A4 enzyme inhibition is irreversible inhibition, in which the inhibitor is irreversibly bound to the enzyme by covalent bonds. Such a bond cannot be easily broken; therefore, the enzyme remains permanently inactive. One of the main characteristics of these inhibitions of the CYP3A4 enzyme is that it takes time, that is, it is a time-dependent inhibition [18].
To test this type of inhibition, special experimental guidelines are implemented that suggest prior pre-incubation of the enzyme with the inhibitor to ensure sufficient time for enzyme inactivation. Only then is nicotinamide adenine dinucleotide phosphate (NADPH) added to the incubation mixture, which serves as a source of electrons in the case of testing CYP3A4 inhibition. NADPH is most often added in the form of a generating system. Another characteristic of this type of inhibition is that the IC50 value cannot be reliably used as a basic indicator of inhibition potency, but other parameters must be considered [63]. Such inhibitions are not characteristic of CYP3A4 enzymes [64], but direct inhibition, as well as metabolism-dependent inhibition, are most often observed.
When testing direct inhibition, the generating system is immediately added to the incubation mixture, while for metabolism-dependent inhibition preincubation with NADPH is carried out. Certain inhibitors of the CYP3A4 enzyme can also act in such a way as to show pseudo-irreversible inhibition. Pseudo-irreversible inhibition or quasi-irreversible inhibition occurs when the inhibitor binds to heme, that is, to the ferrous form of heme iron, whereby a stable complex is formed. Apparently, this type of inhibition should be considered irreversible. However, if there is a possibility for the same enzyme to return to its active form in in vitro conditions (for example, by using an oxidant along with dialysis), then one can observe this unusual phenomenon. One such example of an inhibitor is diltiazem [65]. Some of the selected CYP3A4 inhibitors and their mechanism of inhibition (binding of the inhibitor to the protein and/or heme) are shown in Table 2.
Inhibition of the CYP3A4 enzyme must also be considered in a certain additional context. It is especially important to know on which material the inhibition was evaluated, to better determine the environment in which the inhibition occurs. Tests of the inhibitory effect are most often conducted on the isolated CYP3A4 enzyme. This is a valuable approach that allows the use of an isolated enzyme to investigate inhibitory effects on CYP3A4. It allows researchers to control for a range of factors that may influence research results and to study inhibition at the molecular level. However, the inhibitory potential of the CYP3A4 enzyme is also often investigated on microsomes, which are obtained by centrifugation of tissue homogenates of mice, rats, or human cells. Enzyme activity is often evaluated on human liver microsomes (HLM), human intestinal microsomes (HIM), and rat/mouse liver microsomes (RLM/MLM). The advantage of this method is better enzyme activity due to binding to membranes [18,77]. For testing CYP enzyme expression, the use of bacterial cells (E. coli) or baculovirus systems (baculosomes) obtained from insect cells is also considered. It is worth mentioning the use of hepatocytes for these purposes, especially if one wants to assess the toxicity of the effects of drugs in vitro [18].

3. Flavonoids

Flavonoids are a diverse group of plant pigments that exhibit a wide range of biological activities, making them of great interest to both scientists and the public alike. These naturally occurring compounds are found in a variety of fruits, vegetables, and beverages, and they are responsible for the vibrant colors in many plants [78]. The term flavonoids comes from the Latin word flavus which means yellow; this refers to their characteristic to give color to plants. The basic structure of flavonoids follows the polyphenolic concept, it consists of 15 carbon atoms that are connected to each other in a structure made of 3 different rings (A, B and C), of which two rings (A and B) are aromatic. The structure is connected in the form of a C6-C3-C6 group (Figure 3).
Of the three benzene rings of the basic structure of flavonoids, rings A and C are mutually condensed, while ring C is substituted with an oxygen atom in position 1 (chromane ring). A benzene ring (B) is attached to the C2 position of the chromane ring. Depending on the basic structure of flavonoids, different groups and subgroups of flavonoids can be classified. This further division is based on different substituents on the basic structure of flavonoids, but also on the degrees of oxidation and saturation of certain subgroups of flavonoids [79]. Thus, the following subgroups are most often described in the available literature: flavones, flavonols, flavanones, flavanonols, flavanols (catechins), anthocyanins, isoflavonoids and chalcones (Figure 4).
Flavones, the simplest flavonoids, possess a double-bonded oxygen atom at the C4 position and a double bond between the C2 and C3 atoms. Flavonols, closely related to flavones, carry an additional hydroxyl group at the C3 position, enhancing their antioxidant and anti-inflammatory properties. Flavanones (dihydroflavones) lack the C2-C3 double bond, resulting in a more compact structure. Flavanonols, akin to flavanones, feature a hydroxyl group at the C3 position and a double-bonded oxygen atom at the C4 position. Catechins (flavanols), characterized by the presence of hydroxyl groups at the C3 position, are particularly abundant in green tea and other plants. Anthocyanins, the most colorful flavonoids, lack a substituted oxygen atom and a hydroxyl group, exhibiting a unique structural arrangement with double bonds at the O1-C2 and C3-C4 positions. Their protonated oxygen atom in position 1 contributes to their vibrant red, blue, or purple hues. Isoflavonoids, a special subgroup of flavonoids, exhibit a unique molecular arrangement with ring B attached to the C3 position, rather than the C2 position as in other flavonoids. This structural deviation imparts specific biological activities to isoflavonoids, particularly their role in estrogen regulation. Chalcones, another flavonoid subgroup, deviate further from the typical flavonoid structure by lacking a ring C. The absence of the oxygen atom at position 1 disrupts the linkages between ring A and C, resulting in an open ring configuration. These diverse flavonoid subgroups, with their intricate structural variations, collectively contribute to the rich tapestry of plant pigments and their remarkable biological properties, ranging from antioxidant and anti-inflammatory effects to potential therapeutic applications.
Flavonoids are intricately synthesized through a multi-step process involving the condensation of acetate and shikimate pathway intermediates [80]. This intricate biosynthetic pathway, spanning several steps, orchestrates the transformation of simple starting materials into the complex structures of flavonoids. The initial step in flavonoid biosynthesis involves the condensation of p-coumaric acid, an acetate-derived intermediate, with 3-deoxy-D-arabinoheptulosonate-7-phosphate (DAHP), a shikimate pathway intermediate. This reaction is catalyzed by flavanone synthase (FLS), an enzyme that initiates the flavonoid branch of the shikimate pathway. The resulting intermediate, 4-coumaroyl-coenzyme A, undergoes further modifications, including hydroxylation, dehydration, and rearrangement reactions, leading to the formation of a series of intermediates with increasing complexity [81]. These intermediates serve as precursors for the synthesis of various flavonoid subgroups, including flavones, flavonols, flavanones, and anthocyanins [82]. The biosynthesis of flavonoids is regulated by a network of transcription factors, including MYB, WRKY, and bHLH factors, that respond to environmental cues [83]. These factors orchestrate the expression of flavonoid biosynthetic genes, ensuring that the plant produces the appropriate levels of these compounds to respond to the prevailing environmental conditions. Flavonoids play a multitude of roles in plant biology, contributing to their resilience and adaptability. Their involvement in plant defense against pathogens and herbivores is well-documented [84,85,86]. Flavonoids can act as signaling molecules, attracting beneficial microbes, or deterring pests. Additionally, they can directly interfere with pathogen growth or herbivore feeding mechanisms. Photosynthesis, the process by which plants convert light energy into chemical energy, is another area where flavonoids exhibit vital functions. Flavonoids act as antioxidants, protecting photosynthetic pigments from damage by reactive oxygen species (ROS) generated during photosynthesis. This protective role is crucial for maintaining the efficiency of photosynthesis and ensuring the overall health of the plant [87]. Moreover, flavonoids contribute to the plant's overall antioxidant capacity, mitigating the harmful effects of ROS generated from various sources, including environmental stressors and metabolic processes. This antioxidant activity is attributed to the ability of flavonoids to scavenge ROS and neutralize their oxidizing potential, thereby protecting cellular components from damage.
Flavonoids are ubiquitous in the plant kingdom, imparting a spectrum of colors ranging from yellow and orange to red and purple. Their presence is particularly pronounced in fruits, vegetables, and beverages, making them a significant component of the human diet [88]. So far, over 10,000 flavonoid compounds have been isolated and identified [89]. The distribution of flavonoids within plant tissues is highly variable, influenced by factors such as species, developmental stage, and environmental conditions. Generally, flavonoids are concentrated in the photosynthetic tissues, including leaves, fruits, and flowers [79]. This is due to their role in mediating plant responses to environmental stressors, such as ultra-violet (UV) radiation and pathogen attack. Fruits and vegetables are the primary sources of flavonoids in the human diet. Common dietary sources include berries, citrus fruits, apples, onions, grapes, tea, and red wine [90]. These foods contribute significantly to the daily intake of flavonoids, providing a rich source of antioxidants and potential health benefits.
Flavonoids have garnered considerable attention for their potential health benefits. These compounds play a crucial role in plant biology, serving as antioxidants and contributing to various physiological processes. Flavonoids exhibit a remarkable range of biological activities, including antiangiogenic [91], anticancer [92], antihypertensive [93], antimalarial [94], antimicrobial [95], antioxidant [94], antiproliferative [94], antitumor [94], cardioprotective [96], neuroprotective [97] and many other effects. Anti-inflammatory effects of flavonoids are attributed to their ability to modulate inflammatory signaling pathways. They can inhibit the production of pro-inflammatory mediators, such as cytokines and prostaglandins, and enhance the production of anti-inflammatory molecules, such as nitric oxide. This regulation of inflammation contributes to the prevention and management of chronic inflammatory conditions [98]. Anti-thrombotic properties of flavonoids are also noteworthy. They can inhibit the aggregation of platelets, the blood cells responsible for forming clots. This inhibition reduces the risk of blood clot formation, which can lead to stroke, heart attack, and other cardiovascular complications [99]. While more research is needed to fully elucidate the mechanisms underlying these benefits, accumulating evidence suggests that flavonoids play a protective role in various aspects of human health.
Humans are exposed to flavonoids via the vegetables and fruits they eat, beverages they drink and the diet supplements they take. The number of flavonoids in a food can vary depending on the variety of the food, how it is grown, and how it is processed. For example, strawberries that are grown in sunlight have more flavonoids than strawberries that are grown in shade. Flavonoids are also sensitive to heat and light. This means that they can break down when foods are cooked or stored in direct sunlight. The consumption of flavonoids and the exposure of people to flavonoids depends significantly from country to country, and is dependent on the cultures of a particular society, since it directly follows the eating habits of the population. In addition, it is very demanding to calculate the exact intake of flavonoids since the content of flavonoids in vegetables and fruits can vary significantly from region to region. However, there is some research on this topic. The global consumption of flavonoids ranges from 150 to 600 mg/day depending on the region of the world [100]. For example, Hollman and Katan (1999) calculated that the average intake of flavones and flavonols in the Netherlands is approximately 23 mg/day. According to their claims, the main sources were tea, onions and apples [101]. Although it is to be expected that Mediterranean countries will have a higher consumption of flavonoids, in the study conducted by Zamora-Ros et al. (2013) [102], an intake of 250 to 400 mg/day was determined, while in non-Mediterranean countries, an intake of 350 to 600 mg/day was determined. It is believed that the reason lies in the fact that the consumption of different types of tea is higher in non-Mediterranean countries. The average intake of flavonoids in the United States is 250 to 400 mg/day [103], while the average intake in Australia is much higher and amounts to 650 to 700 mg/day. There is limited data from Asian countries; it is assumed that the average intake of flavonoids in China is up to 225 mg/day [105], and in South Korea it is slightly higher (320 mg/day) [106]. All these indicators speak in favor of the fact that the intake of flavonoids in humans is diverse, but certainly significant.
The mechanism of action of flavonoids by which they achieve different health effects is still extensively studied. One of the most frequently studied mechanisms of action is the inhibition of certain enzymes that can lead to certain pathological conditions. Thus, it is known that flavonoids can inhibit, for example, enzymes involved in cholesterol metabolism, such as 3-hydroxy-3-methylglutaryl coenzyme A reductase in Vero cells [107], enzymes involved in low density lipoprotein oxidation such as 5-lipoxygenase [108] , enzymes involved in inflammation and painful conditions such as cyclooxygenase 1 and 2 [109] or enzymes involved in tumor growth and proliferation [110]. The inhibitory effect of flavonoids on CYP enzymes, especially on the CYP3A4 enzyme [4,36,48,58] is certainly the most important for drug metabolism.

3.1. Flavones

Of all the tested flavonoids, most of them belong to the flavones group. In this group, 23 flavonoids were observed for which inhibitory activity against CYP3A4 enzymes was tested. The average IC50 value of the tested flavonoids was 38.36 μM, while the average remaining enzyme activity after incubation with flavonoids was 59.0%. In 40 reviewed experiments, it was observed that chrysin behaves as a strong inhibitor of the CYP3A4 enzyme, with an IC50 value of 0.6 ± 0.5 μM in two different independent tests [111,112] (1, 43) (Table 3). 25 flavones showed an intermediate inhibitory effect on the CYP3A4 enzyme, where certain experiments with much lower IC50 values ​​compared to the others should be highlighted. Apigenin has shown quite a low IC50 value in several different tests. In the test conducted by Cho, Choi and Burm apigenin had an IC50 value of 1.47 μM, where testosterone was used as a substrate, and the tests were performed on human liver microsomes [113]. When midazolam was used as a substrate for the CYP3A4 enzyme, this flavone showed an IC50 value of 2.3 ± 0.3 μM [114]. Slightly higher values ​​(8.4 μM) were obtained by Kondža et al. when nifedipine was used as a marker substrate on the CYP3A4 enzyme [111]. XY tested numerous flavonoids and flavonoid derivatives on the CYP3A4 enzyme. They used midazolam as a marker substrate. The values ​​obtained for 2'-methoxy-5,7-dihydroxyflavones and 3'4'-dimethoxy-5,7-dihydroxyflavones (2 and 6.5 μM, respectively) should be highlighted [114]. Luteolin also proved to be a potent inhibitor, which in the test done by Scott et al. [115] showed a significant IC50 value of 4.62 ± 1.26 μM. Acacetin also proved to be a significant inhibitor of the enzyme in the Shimada et al. and Scott et al. assays. IC50 values ​​of 6.5 and 6.25 ± 0.96 μM were observed [114,115].
Tests of the remaining enzyme activity were performed on similar flavones, using different concentrations of inhibitors (Table 4). Such results generally follow the results of IC50 values. The effectiveness of acacetin, chrysin and α-naphthoflavone should be singled out. The remaining enzyme activity in these cases was 5 ± 4%, 17 ± 3% and 6.8% [116,117].

3.2. Flavonols

In the group of flavonols, 12 different flavonoids were observed in 17 ex-experimental studies. A review of flavonoids did not reveal a single strong CYP3A4 enzyme inhibitor according to current guidelines. 14 flavonoids behaved as intermediate inhibitors of CYP3A4 enzyme, while 3 flavonoids were weak inhibitors. The average IC50 value of the observed inhibitors was 45.69 μM, while the average remaining enzyme activity was 58.99%. Of all observed flavonols, galangin had the lowest IC50 value, which was 2.3 μM [114]. This test was performed on the CYP3A4 enzyme with midazolam as a substrate (Table 5). It is interesting to note that attention should be paid to the substrate that is applied and the material on which the test is carried out. Galangin was the subject of research by Ho et al., who in their work established an IC50 value of galangin as high as 117 μM [120]. It should be taken into account that this research was conducted on human liver microsomes with quinine as a marker substrate. Valid literature for the CYP3A4 enzyme suggests the use of testosterone as a substrate marker with nifedipine as additional confirmation [18]. Chrysosplenetin also proved to be a significant inhibitor of the tested enzymes. An IC50 value of 3.38 μM was observed. Midazolam was used as a marker substrate, and tests were performed on rat liver microsomes [124].
The remaining enzyme activity was tested with different inhibitor concentrations; from 1 μM to 188 μM (Table 6). Myricetin caused the greatest inhibition of the CYP3A4 enzyme, where at a concentration of 100 μM, it reduced the activity of the enzyme to 6.4% [120]. Kaempferitrin and dihydromyricetin also at a concentration of 100 μM caused a decrease in CYP3A4 enzyme activity to a value of 18% [125,126]. A similar inhibitory effect (18.27 ± 14.55%) was also demonstrated using chrysosplenetin (50 μM) [124].

3.3. Flavanones

In the group of flavanones, 35 different experiments were reviewed that examined the activity of 19 different flavonoids. The average IC50 value of this group was 120.70 μM, while the average residual activity of the CYP3A4 enzyme was 61.54%. Kusehnol I, leachianone A and sophoraflavone G proved to be the most powerful inhibitors [131]. These flavonoids showed a significant IC50 value of 0.57, 0.69 and 0.78 μM (Table 7). At the same time, there are 3 strong inhibitors in this group. 10 weak inhibitors were observed in different experiments, while most were intermediate inhibitors. It is worth mentioning other inhibitors from the subgroup of prenylated flavanones, such as kushenol M and kushenol C, which also showed a significant IC50 value (1.29 and 3.95 μM, respectively) on human liver microsomes with the use of midazolam [131]. Pinocembrin is a naturally occurring flavonoid that in various studies shows inhibitory activity against various enzymes, including CYP3A4 enzymes. In this review, similar IC50 values ​​of 4.30 to 5.00 μM were observed using midazolam as a substrate on human liver microsomes [111].
In the examination of the remaining activity of the CYP3A4 enzyme after the use of flavonoids as inhibitors, alpinetin proved to be the most potent inhibitor. At a concentration of 100 μM, it caused an inhibitory effect on CYP3A4, whereby the activity of this enzyme decreased to 20% on human liver microsomes [132] (Table 8). Pinocembrin, for example, showed a smaller effect. The remaining activity of the enzyme was approximately 50% [116], however, the method of conducting the experiment and the incubation and pre-incubation processes should be taken into account in order to accurately speak about the inhibitory effect of this flavonoid.

3.4. Flavanonols, Flavanols/Catechins, Isoflavonoids and Chalcones

Other observed groups of flavonoids are flavanonols, flavanols/catechins, isoflavonoids and chalcones. The only tested flavonoid in the group of flavanonols was taxifolin. Taxifolin proved to be a weak inhibitor of CYP3A4 with an IC50 value of 68.9 ± 2.3 μM [115] (Table 9). A total of 8 different experiments and 4 different types of flavonoids were reviewed in the flavanols/catechins group. Most of them were intermediate potent flavonoids, with one, (-)-catechin-3-O-gallate, showing a weak inhibitory potential [134]. The average IC50 value of this group was 37.22 μM, while the average residual value of the enzyme was 53% (Table 10). Examining the group of isoflavonoids, 4 different experimental processes and 3 different flavonoids were observed. The average IC50 value was 43.73 μM. The most powerful inhibitor in this group was 8-methoxycirsilineol with an IC50 value of 1.71 ± 0.3 μM [118]. In the group of chalcones, 3 different experiments and 3 different flavonoids were observed. These are flavonoids of intermediate potential with an average IC50 value of 33.7 μM.

4. Conclusions

Flavonoids are a diverse group of phytochemicals found in fruits, vegetables, and beverages. They're responsible for the vibrant colors of many plants, as well as some of their unique flavors and aromas. Certain flavonoids, notably kusehnol I, chrysin, leachianone A, and sophoraflavone G, exhibit potent in vitro inhibitory effects on CYP3A4. While moderate dietary intake of these flavonoids typically poses minimal risk due to complex interactions and lower individual concentrations, high-dose supplementation or concurrent use with CYP3A4-metabolized medications warrants closer examination. The inhibitory capacity of these flavonoids towards CYP3A4 can significantly elevate blood levels of co-administered drugs by reducing their metabolic clearance. This pharmacological interaction can manifest as increased adverse effects and reduced drug efficacy among others. However, the clinical significance of this interaction in dietary contexts remains multifaceted. The interplay between various dietary constituents, individual metabolic capacities, and the specific flavonoid profile of different food sources complicates the prediction of in vivo effects. While dietary considerations are generally minor, high-dose flavonoid supplementation requires prudent evaluation alongside individual medication regimens involving CYP3A4 substrates to minimize potential adverse interactions. Physicians, pharmacists, health workers, workers in the field of pharmaceutical and food industry should be aware of the possibilities of the strong and intermediate inhibitions shown in this review.

Author Contributions

M.K. conceptualized the chapter, obtained the data, did the article research, and supervised the writing; I.B. wrote the draft and edited the chapter; S.J. obtained the data, carried out the formal analysis and validated the conclusions. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bailey, D.G.; Dresser, G.K. Natural products and adverse drug interactions. CMAJ 2004, 170(10), 1531–2. [Google Scholar] [CrossRef]
  2. Ruschitzka, F.; Meier, P.J.; Turina, M.; Luscher, T.T.; Noll, G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000, 355, 548–9. [Google Scholar] [CrossRef]
  3. Piscitelli, S.C.; Burstein, A.H.; Chaitt, D.; Alfaro, R.M.; Falloon, J. Indinavir concentrations and St John's wort. Lancet 2000, 355, 547–8. [Google Scholar] [CrossRef] [PubMed]
  4. Kondža, M.; Mandić, M.; Ivančić, I.; Vladimir-Knežević, S.; Brizić, I. Artemisia annua L. Extracts Irreversibly Inhibit the Activity of CYP2B6 and CYP3A4 Enzymes. Biomedicines 2023, 11(1), 232. [Google Scholar] [CrossRef]
  5. Choudhury, A.; Singh, P.A.; Bajwa, N.; Dash, S.; Bisht, P. Pharmacovigilance of herbal medicines: Concerns and future prospects. J Ethnopharmacol 2023, 309, 116383. [Google Scholar] [CrossRef] [PubMed]
  6. Górniak, I.; Bartoszewski, R.; Króliczewski, J. Comprehensive review of antimicrobial activities of plant flavonoids. Phytochem. Rev 2019, 18, 241–272. [Google Scholar] [CrossRef]
  7. Biharee, A.; Sharma, A.; Kumar, A.; Jaitak, V. Antimicrobial flavonoids as a potential substitute for overcoming antimicrobial resistance. Fitoterapia 2020, 146, 104720. [Google Scholar] [CrossRef]
  8. Donadio, G.; Mensitieri, F.; Santoro, V.; Parisi, V.; Bellone, M.; De Tommasi, N.; Izzo, V.; Piaz, F.D. Interactions with Microbial Proteins Driving the Antibacterial Activity of Flavonoids. Pharmaceutics 2021, 13, 660. [Google Scholar] [CrossRef] [PubMed]
  9. Song, M.; Liu, Y.; Li, T.; Liu, X.; Hao, Z.; Ding, S.; Panichayupakaranant, P.; Zhu, K.; Shen, J. Plant Natural Flavonoids Against Multidrug Resistant Pathogens. Adv Sci 2021, 8, 2100749. [Google Scholar] [CrossRef] [PubMed]
  10. Ruddock, P.S.; Charland, M.; Ramirez, S.; López, A.; Towers, G.H.N.; Arnason, J.T.; Liao, M.; Dillon, J.A.R. Antimicrobial Activity of Flavonoids from Piper lanceaefolium and Other Colombian Medicinal Plants Against Antibiotic Susceptible and Resistant Strains of Neisseria gonorrhoeae. Sex Transm Dis 2011, 38, 82–88. [Google Scholar] [CrossRef] [PubMed]
  11. Bibi, Z. Role of cytochrome P450 in drug interactions. Nutr Metab 2008, 5, 27. [Google Scholar] [CrossRef] [PubMed]
  12. Manikandan, P.; Nagini, S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr Drug Targets 2018, 19(1), 38–54. [Google Scholar] [CrossRef] [PubMed]
  13. Coleman, T.; Podgorski, M.N.; Doyle, M.L.; Scaffidi-Muta, J.M.; Campbell, E.C.; Bruning, J.B.; De Voss, J.J.; Bell, S.G. Cytochrome P450-catalyzed oxidation of halogen-containing substrates. J Inorg Biochem 2023, 244, 112234. [Google Scholar] [CrossRef]
  14. Rendić, S.; Guengerich, F.P. Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals. Chem Res Toxicol 2015, 28, 38–42. [Google Scholar] [CrossRef] [PubMed]
  15. Zhao, M.; Ma, J.; Li, M.; Zhang, Y.; Jiang, B.; Zhao, X.; Huai, C.; Shen, L.; Zhang, N.; He, L.; Qin, S. Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int J Mol Sci 2021, 22(23), 12808. [Google Scholar] [CrossRef]
  16. Gao, L.; Tu, Y.; Wegman, P.; Wingren, S.; Eriksson, L.A. A mechanistic hypothesis for the cytochrome P450-catalyzed cis-trans isomerization of 4-hydroxytamoxifen: an unusual redox reaction. J Chem Inf Model 2011, 51(9), 2293–301. [Google Scholar] [CrossRef] [PubMed]
  17. Medić Šarić, M.; Rendić, S. Cytochrome P450 Enzymes. In Metabolizam lijekova i odabranih ksenobiotika, 1st ed.; Medić-Šarić, M., Ed.; Medicinska naklada: Zagreb, Croatia, 2013; p. 136. [Google Scholar]
  18. Bojić, M. Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450. Farm Glas 2015, 71, 229–242. [Google Scholar]
  19. Danielson, P.B. The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002, 3, 561–597. [Google Scholar] [CrossRef]
  20. Klyushova, L.S.; Perepechaeva, M.L.; Grishanova, A.Y. The Role of CYP3A in Health and Disease. Biomedicines 2022, 10, 2686. [Google Scholar] [CrossRef]
  21. Stipp, M.C.; Acco, A. Involvement of cytochrome P450 enzymes in inflammation and cancer: A review. Cancer Chemother Pharmacol 2021, 87, 295–309. [Google Scholar] [CrossRef]
  22. Burlaka, V.S.; Burlaka, A.A. Cytochrome P450 content in primary tumors and liver metastases of patients with metastatic colorectal cancer. Exp Oncol 2020, 42, 1–3. [Google Scholar] [CrossRef] [PubMed]
  23. Barros-Oliveira, M.D.C.; Costa-Silva, D.R.; Dos Santos, A.R.; Pereira, R.O.; Soares-Júnior, J.M.; Silva, B.B.D. Influence of CYP19A1 gene expression levels in women with breast cancer: A systematic review of the literature. Clinics 2021, 76, e2846. [Google Scholar] [CrossRef] [PubMed]
  24. Dutour, R.; Poirier, D. Inhibitors of cytochrome P450 (CYP) 1B1. Eur J Med Chem 2017, 135, 296–306. [Google Scholar] [CrossRef] [PubMed]
  25. Karkhanis, A.; Hong, Y.; Chan, E.C.Y. Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy. Biochem Pharmacol 2017, 135, 12–21. [Google Scholar] [CrossRef] [PubMed]
  26. Karlgren, M.; Ingelman-Sundberg, M. Tumor-specific expression of CYP2W1: Its potential as a drug target in cancer therapy. Expert Opin Ther Targets 2007, 11, 61–67. [Google Scholar] [CrossRef] [PubMed]
  27. Finta, C.; Zaphiropoulos, P. The human cytochromeP450 3A locus. Gene evaluation by capture of downstream exons. Gene 2000, 260, 13–23. [Google Scholar] [CrossRef] [PubMed]
  28. Johnson, T.N.; Tucker, G.T.; Rostami-Hodjegan, A. Development of CYP2D6 and CYP3A4 in the first year of life. CPT 2008, 83(5), 670–1. [Google Scholar] [CrossRef] [PubMed]
  29. Kudzi, W.; Dodoo, A.N.; Mills, J.J. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 2010, 11, 111. [Google Scholar] [CrossRef] [PubMed]
  30. Shapiro, L.E.; Shear, N.H. Drug interactions: Proteins, pumps, and P-450s. J Am Acad Dermatol 2002, 7, 467–84. [Google Scholar] [CrossRef]
  31. Rendić, S.; Guengerich, F.P. Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals. Chem Res Toxicol 2015, 28, 38–42. [Google Scholar] [CrossRef] [PubMed]
  32. Zanger, U.M.; Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013, 138(1), 103–41. [Google Scholar] [CrossRef] [PubMed]
  33. Hirota, T.; Fujita, Y.; Ieiri, I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol 2020, 16(9), 809–822. [Google Scholar] [CrossRef] [PubMed]
  34. Hunt, C.M.; Westerkam, W.R.; Stave, G.M. Effect of age and gender on the activity of human hepatic CYP3A4. Biochem Pharmacol 1992, 44, 275–28. [Google Scholar] [CrossRef] [PubMed]
  35. Kramlinger, V.M.; Rojas, M.A.; Kanamori, T.; Guengerich, F.P. Cytochrome P450 3A Enzymes Catalyze the O-6-Demethylation of Thebaine, a Key Step in Endogenous Mammalian Morphine Biosynthesis. JBC 2015, 290, 20200–20210. [Google Scholar] [CrossRef] [PubMed]
  36. Schmiedlin-Ren, P.; Edwards, D.J.; Fitzsimmons, M.E.; He, K.; Lown, K.S.; Woster, P.M.; Rahman, A.; Thummel, K.E.; Fisher, J.M.; Hollenberg, P.F.; Watkins, P.B. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Disp 1997, 25, 1228–33. [Google Scholar]
  37. Chu, V.; Einolf, H.J.; Evers, R.; Kumar, G.; Moore, D.; Ripp, S.; Silva, J.; Sinha, V.; Sinz, M.; Skerjanec, A. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos 2009, 37, 1339–54. [Google Scholar] [CrossRef] [PubMed]
  38. Gibson, G.G.; Plant, N.J.; Swales, K.E.; Ayrton, A.; El-Sankary, W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002, 32, 165–206. [Google Scholar] [CrossRef]
  39. Wang, K.; Chen, S.; Xie, W.; Wan, Y.J. Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem Pharmacol 2008, 75(11), 2204–13. [Google Scholar] [CrossRef]
  40. Zhang, J.G.; Ho, T.; Callendrello, A.L.; Crespi, C.L.; Stresser, D.M. A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with β-naphthoflavone, phenobarbital and rifampicin. Drug Metab Lett 2010, 4, 185–194. [Google Scholar] [CrossRef]
  41. Pascussi, J.M.; Robert, A.; Nguyen, M.; Walrant-Debray, O.; Garabedian, M. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005, 115, 177–186. [Google Scholar] [CrossRef]
  42. Gibbons, J.A.; de Vries, M.; Krauwinkel, W.; Ohtsu, Y.; Noukens, J.; van der Walt, J.S.; Mol, R.; Mordenti, J.; Ouatas, T. Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clin Pharmacokinet 2015, 54(10), 1057–69. [Google Scholar] [CrossRef] [PubMed]
  43. Johannessen, S.I.; Landmark, C.J. Antiepileptic drug interactions - principles and clinical implications. Curr Neupharmacol 2010, 8(3), 254–67. [Google Scholar] [CrossRef] [PubMed]
  44. Fuhr, L.M.; Marok, F.Z.; Hanke, N.; Selzer, D.; Lehr, T. Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach. Pharmaceutics 2021, 13(2), 270. [Google Scholar] [CrossRef] [PubMed]
  45. Nallani, S.C.; Glauser, T.A.; Hariparsad, N.; Setchell, K.; Buckley, D.J.; Buckley, A.R.; Desai, P.B. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia 2003, 44(12), 1521–8. [Google Scholar] [CrossRef] [PubMed]
  46. Aquinos, B.M.; García Arabehety, J.; Canteros, T.M.; de Miguel, V.; Scibona, P.; Fainstein-Day, P. Adrenal crisis associated with modafinil use. Medicina 2021, 81(5), 846–849. [Google Scholar] [PubMed]
  47. Han, E.H.; Kim, H.G.; Choi, J.H.; Jang, Y.J.; Lee, S.S.; Kwon, K.I.; Kim, E.; Noh, K.; Jeong, T.C.; Hwang, Y.P.; Chung, Y.C.; Kang, W.; Jeong, H.G. Capsaicin induces CYP3A4 expression via pregnane X receptor and CCAAT/enhancer-binding protein β activation. Mol Nutr Food Res 2012, 56(5), 797–809. [Google Scholar] [CrossRef] [PubMed]
  48. Roby, C.A.; Anderson, G.D.; Kantor, E.; Dryer, D.A.; Burstein, A.H. St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000, 67(5), 451–7. [Google Scholar] [CrossRef] [PubMed]
  49. Beunk, L.; Nijenhuis, M.; Soree, B.; de Boer-Veger, N.J.; Buunk, A.M.; Guchelaar, H.J.; Houwink, E.J.F.; Risselada, A.; Rongen, G.A.P.J.M.; van Schaik, R.H.N.; Swen, J.J.; Touw, D.; van Westrhenen, R.; Deneer, V.H.M.; van der Weide, J. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet 2023. Advance online publication. [Google Scholar] [CrossRef]
  50. Wen, J.; Chen, Y.; Zhao, M.; Hu, W.; Xiao, Y.W. Effects of clarithromycin on the pharmacokinetics of tacrolimus and expression of CYP3A4 and P-glycoprotein in rats. Fundam Clin Pharmacol 2023, 37(4), 843–848. [Google Scholar] [CrossRef] [PubMed]
  51. Kumaraswami, K.; Katkam, S.K.; Aggarwal, A.; Sharma, A.; Manthri, R.; Kutala, V.K.; Rajasekhar, L. Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients. Pharmacogenomics 2017, 18(15), 1401–1411. [Google Scholar] [CrossRef] [PubMed]
  52. Zhou, S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008, 9(4), 310–22. [Google Scholar] [CrossRef]
  53. Bagdasaryan, A.A.; Chubarev, V.N.; Smolyarchuk, E.A.; Drozdov, V.N.; Krasnyuk, I.I.; Liu, J.; Fan, R.; Tse, E.; Shikh, E.V.; Sukocheva, O.A. Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy. Cancers 2022, 14(21), 5436. [Google Scholar] [CrossRef]
  54. Bansal, S.; Zamarripa, C.A.; Spindle, T.R.; Weerts, E.M.; Thummel, K.E.; Vandrey, R.; Paine, M.F.; Unadkat, J.D. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. Clin Pharmacol Ther 2023, 114(3), 693–703. [Google Scholar] [CrossRef] [PubMed]
  55. Bilbao-Meseguer, I.; Jose, B.S.; Lopez-Gimenez, L.R.; Gil, M.A.; Serrano, L.; Castaño, M.; Sautua, S.; Basagoiti, A.D.; Belaustegui, A.; Baza, B.; Baskaran, Z.; Bustinza, A. Drug interactions with sunitinib. J Oncol Pharm Pract 2015, 21(1), 52–66. [Google Scholar] [CrossRef] [PubMed]
  56. Ramos, K.N.; Gregornik, D.; Ramos, K.S. Pharmacogenomics insights into precision pediatric oncology. Curr Opin Pediatr 2021, 33(6), 564–569. [Google Scholar] [CrossRef] [PubMed]
  57. Enting, R.H.; Hoetelmans, R.M. Antiretroviral drugs and the central nervous system. AIDS. 1998, 12, 1941–55. [Google Scholar] [CrossRef] [PubMed]
  58. Shen, G.L.; Liang, A.H.; Zhao, Y.; Cao, C.Y.; Liu, T.; Li, C.Y.; Odd, G.N. Interaction between four herb compounds and a western drug by CYP3A4 enzyme metabolism in vitro. China J Chin Mater Med. 2009, 34, 1705–1711. [Google Scholar]
  59. Qin, M.N.; Liu, R.; Liu, G.F.; Dong, F. Effects of Breviscapines Injections on CYP Activities in Rat Liver Microsomes in vitro. China Pharm 2012, 15, 147–150. [Google Scholar]
  60. Greenblatt, D.J.; Zhao, Y.; Venkatakrishnan, K.; Duan, S.X.; Harmatz, J.S.; Parent, S.J.; Court, M.H.; von Moltke, L.L. Mechanism of cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol 2011, 63(2), 214–21. [Google Scholar] [CrossRef] [PubMed]
  61. Deodhar, M.; Al Rihani, S.B.; Arwood, M.J.; Darakjian, L.; Dow, P.; Turgeon, J.; Michaud, V. Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. Pharmaceutics. 2020, 12(9), 846. [Google Scholar] [CrossRef] [PubMed]
  62. A Guide to In Vitro CYP Inhibition Studies: Elements of Study Design and Important Considerations in Data Analysis. Available online: https://bioivt.com/resources/articles-publications/a-guide-to-in-vitro-cyp-inhibition-studies-elements-of-study-design-and-important-considerations-in-data-analysis (accessed on 7 December 2023).
  63. Fowler, S.; Zhang, H. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J 2008, 10(2), 410–24. [Google Scholar] [CrossRef] [PubMed]
  64. Bojić, M.; Barbero, L.; Dolgos, H.; Freisleben, A.; Galleman, D.; Riva, S.; Guengerich, F.P. Time- and NADPH-dependent inhibition of cytochrome P450 3A4 by the cyclopentapeptide cilengitide: significance of the guanidine group and accompanying spectral changes. Drug Metabol Disp 2014, 4, 1438–1446. [Google Scholar] [CrossRef] [PubMed]
  65. Lee, J.Y.; Lee, S.Y.; Oh, S.J.; Lee, K.H.; Jung, Y.S.; Kim, S.K. Assesment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition. Chem Biol Interact 2012, 198, 49–56. [Google Scholar] [CrossRef] [PubMed]
  66. Polasek, T. M.; Elliot, D. J.; Lewis, B. C.; Miners, J. O. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Pharmacol Exp Ther 2000, 311(3), 996–1007. [Google Scholar] [CrossRef] [PubMed]
  67. Jones, D. R.; Ekins, S.; Li, L.; Hall, S. D. Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos 2007, 35(9), 1466–1475. [Google Scholar] [CrossRef] [PubMed]
  68. Hulskotte, E.G.; Feng, H.P.; Xuan, F.; Gupta, S.; van Zutven, M.G.; O'Mara, E.; Wagner, J.A.; Butterton, J.R. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother 2013, 57(6), 2582–8. [Google Scholar] [CrossRef] [PubMed]
  69. Tinel, M.; Descatoire, V.; Larrey, D.; Loeper, J.; Labbe, G.; Letteron, P.; Pessayre, D. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989, 250(2), 746–751. [Google Scholar] [PubMed]
  70. Masubuchi, Y.; Ose, A.; Horie, T. Diclofenac-Induced Inactivation of CYP3A4 and Its Stimulation by Quinidine. Drug Metab Dispos, 2002; 30, 10, 1143–1148. [Google Scholar] [CrossRef]
  71. Hanioka, N.; Ozawa, S.; Jinno, H.; Tanaka-Kagawa, T.; Nishimura, T. ando, M.; Sawada, J. I. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab Dispos 2002, 30(4), 391–396. [Google Scholar] [CrossRef] [PubMed]
  72. Guengerich, F. P. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 1990, 3(4), 363–371. [Google Scholar] [CrossRef]
  73. Iwata, H.; Tezuka, Y.; Kadota, S.; Hiratsuka, A.; Watabe, T. Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit extract. Drug Metab Pharmacokinet 2005, 20(1), 34–45. [Google Scholar] [CrossRef]
  74. Watanabe, A.; Nakamura, K.; Okudaira, N.; Okazaki, O.; Sudo, K. I. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab Dispos 2007, 35(7), 1232–1238. [Google Scholar] [CrossRef]
  75. von Moltke, L. L.; Durol, A. L.; Duan, S. X.; Greenblatt, D. J. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 2000, 56(3), 259–261. [Google Scholar] [CrossRef] [PubMed]
  76. Ernest, C. S.; Hall, S. D.; Jones, D. R. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005, 312(2), 583–591. [Google Scholar] [CrossRef]
  77. Guengerich, F.P. Analysis and Characterization of Enzymes and Nucleic Acids Relevant to Toxicology. In Hayes' Principles and Methods of Toxicology, 6th ed.; Hayes, A.W., Kruger, C.L., Eds.; CRC Press: Boca Raton, FL, USA, 2014; pp. 1906–1964. [Google Scholar]
  78. 78. Shen, N.; Wang, T.; Gan, Q.; Liu, S.; Wang, L.; Jin, B. Plant flavonoids: Classification, distribution, biosynthesis, and antioxidant activity. Food Chem 2022, 383, 132531. [Google Scholar] [CrossRef]
  79. Panche, A.; Diwan, A.; Chandra, S. Flavonoids: An overview. J Nutr Sci 2016, 5, e47. [Google Scholar] [CrossRef] [PubMed]
  80. Liu, W.; Feng, Y.; Yu, S.; Fan, Z.; Li, X.; Li, J.; Yin, H. The Flavonoid Biosynthesis Network in Plants. Int J Mol Sci 2021, 22(23), 12824. [Google Scholar] [CrossRef] [PubMed]
  81. Liu, Z.Q. What about the progress in the synthesis of flavonoid from 2020? Eur J Med Chem 2022, 243, 114671. [Google Scholar] [CrossRef] [PubMed]
  82. Chen, Y.; Cheng, F.B.; Wu, X.R.; Zhu, W.; Liao, J.W.; Jiang, Y.; Zhang, C.; Niu, W.Y.; Yu, Y.; Duan, H.Q.; Qin, N. Flavonoid derivatives synthesis and anti-diabetic activities. Bioorg Chem 2020, 95, 103501. [Google Scholar] [CrossRef] [PubMed]
  83. Zhang, J.; Zhao, H.; Chen, L.; Lin, J.; Wang, Z.; Pan, J.; Yang, F.; Ni, X.; Wang, Y.; Wang, Y.; Li, R.; Pi, E.; Wang, S. Multifaceted roles of WRKY transcription factors in abiotic stress and flavonoid biosynthesis. Front Plant Sci 2023, 14, 1303667. [Google Scholar] [CrossRef] [PubMed]
  84. Mierziak, J.; Kostyn, K.; Kulma, A. Flavonoids as important molecules of plant interactions with the environment. Molecules 2014, 19(10), 16240–65. [Google Scholar] [CrossRef] [PubMed]
  85. Mathesius, U. Flavonoid Functions in Plants and Their Interactions with Other Organisms. Plants 2018, 7(2), 30. [Google Scholar] [CrossRef]
  86. Ramaroson, M.-L.; Koutouan, C.; Helesbeux, J.-J.; Le Clerc, V.; Hamama, L.; Geoffriau, E.; Briard, M. Role of Phenylpropanoids and Flavonoids in Plant Resistance to Pests and Diseases. Molecules 2022, 27, 8371. [Google Scholar] [CrossRef]
  87. Brunetti, C.; Di Ferdinando, M.; Fini, A.; Pollastri, S.; Tattini, M. Flavonoids as antioxidants and developmental regulators: relative significance in plants and humans. Int J Mol Sci 2013, 14(2), 3540–55. [Google Scholar] [CrossRef]
  88. Thilakarathna, S.; Rupasinghe, H. Flavonoid Bioavailability and Attempts for Bioavailability Enhancement. Nutrients 2013, 5, 3367–3387. [Google Scholar] [CrossRef]
  89. Aleksandra Kozłowska, D.S.-W. Flavonoids-food sources and health benefits. Rocz Panstw Zakl Hig 2014, 65, 65. [Google Scholar]
  90. Iwashina, T. Flavonoid properties of five families newly incorporated into the order Caryophyllales (Review). Bull Natl Mus Nat Sci 2013, 39, 25–51. [Google Scholar]
  91. Camero, C.M.; Germanò, M.P.; Rapisarda, A.; D’Angelo, V.; Amira, S.; Benchikh, F.; Braca, A.; De Leo, M. Anti-angiogenic activity of iridoids from Galium tunetanum. Rev Bras de Farmacogn 2018, 28, 374–377. [Google Scholar] [CrossRef]
  92. Zhao, L.; Yuan, X.; Wang, J.; Feng, Y.; Ji, F.; Li, Z.; Bian, J. A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs. Bioorganic Med Chem 2019, 27, 677–685. [Google Scholar] [CrossRef] [PubMed]
  93. Xue, Z.; Wang, J.; Chen, Z.; Ma, Q.; Guo, Q.; Gao, X.; Chen, H. Antioxidant, antihypertensive, and anticancer activities of the flavonoid fractions from green, oolong, and black tea infusion waste. J Food Biochem 2018, 42, e12690. [Google Scholar] [CrossRef]
  94. Patel, K.; Kumar, V.; Rahman, M.; Verma, A.; Patel, D.K. New insights into the medicinal importance, physiological functions and bioanalytical aspects of an important bioactive compound of foods ‘Hyperin’: Health benefits of the past, the present, the future. Beni-Suef Univ J Basic Appl Sc. 2018, 7, 31–42. [Google Scholar] [CrossRef]
  95. Gupta, T.; Kataria, R.; Sardana, S. A Comprehensive Review on Current Perspectives of Flavonoids as Antimicrobial Agent. Curr Top Med Chem 2022, 22(6), 425–434. [Google Scholar] [CrossRef] [PubMed]
  96. Faggio, C.; Sureda, A.; Morabito, S.; Sanches-Silva, A.; Mocan, A.; Nabavi, S.F.; Nabavi, S.M. Flavonoids and platelet aggregation: A brief review. Eur J Pharmacol 2017, 807, 91–101. [Google Scholar] [CrossRef] [PubMed]
  97. Xie, J.; Xiong, J.; Ding, L.-S.; Chen, L.; Zhou, H.; Liu, L.; Zhang, Z.-F.; Hu, X.-M.; Luo, P.; Qing, L.-S. A efficient method to identify cardioprotective components of Astragali Radix using a combination of molecularly imprinted polymers-based knockout extract and activity evaluation. J Chromatogr A 2018, 1576, 10–18. [Google Scholar] [CrossRef] [PubMed]
  98. Al-Khayri, J.M.; Sahana, G.R.; Nagella, P.; Joseph, B.V.; Alessa, F.M.; Al-Mssallem, M.Q. Flavonoids as Potential Anti-Inflammatory Molecules: A Review. Molecules 2022, 27(9), 2901. [Google Scholar] [CrossRef] [PubMed]
  99. Quintal Martínez, J.P.; Segura Campos, M.R. Flavonoids as a therapeutical option for the treatment of thrombotic complications associated with COVID-19. Phytother Res 2023, 37(3), 1092–1114. [Google Scholar] [CrossRef] [PubMed]
  100. An Overview of Global Flavonoid Intake and its Food Sources. Available online: https://www.intechopen.com/chapters/54289 (accessed on 18 November 2023).
  101. Hollman, P.C.; Katan, M.B. Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol 1999, 37(9-10), 937–42. [Google Scholar] [CrossRef] [PubMed]
  102. Zamora-Ros, R.; Knaze, V.; Luján-Barroso, L.; Romieu, I.; Scalbert, A.; Slimani, N.; Hjartåker, A.; Engeset, D.; Skeie, G.; Overvad, K. Differences in dietary intakes, food sources and determinants of total flavonoids between mediterranean and non-mediterranean countries participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Br J Nutr 2013, 109(8), 1498–507. [Google Scholar] [CrossRef]
  103. Chun, O.K.; Chung, S.J.; Song, W.O. Estimated dietary flavonoid intake and major food sources of US adults. J Nutr 2007, 137(5), 1244–52. [Google Scholar] [CrossRef]
  104. Kent, K.; Charlton, K.E.; Russell, J.; Mitchell, P.; Flood, V.M. Estimation of flavonoid intake in older Australians: Secondary Data Analysis of the Blue Mountains Eye Study. J Nutr Gerontol Geriatr 2015, 34(4), 388–98. [Google Scholar] [CrossRef]
  105. Zhang, Z.; He, L.; Liu, Y.; Liu, J.; Su, Y.; Chen, Y. Association between dietary intake of flavonoid and bone mineral density in middle aged and elderly Chinese women and men. Osteoporos Int 2014, 25(10), 2417–25. [Google Scholar] [CrossRef] [PubMed]
  106. Jun, S.; Shin, S.; Joung, H. Estimation of dietary flavonoid intake and major food sources of Korean adults. Br J Nutr 2016, 115(3), 480–9. [Google Scholar] [CrossRef]
  107. Chen, T.H.; Liu, J.C.; Chang, J.J.; Tsai, M.F.; Hsieh, M.H.; Chan, P. The in vitro inhibitory effect of flavonoid astilbin on 3-hydroxy-3-methylglutaryl coenzyme A reductase on Vero cells. Zhon Yi Xue Za Zhi 2001, 64(7), 382–7. [Google Scholar] [CrossRef]
  108. Schewe, T.; Kühn, H.; Sies, H. Flavonoids of cocoa inhibit recombinant human 5-lipoxygenase. J Nutr 2002, 132(7), 1825–9. [Google Scholar] [CrossRef]
  109. Ribeiro, D.; Freitas, M.; Tomé, S.M.; Silva, A.M.; Laufer, S.; Lima, J.L.; Fernandes, E. Flavonoids inhibit COX-1 and COX-2 enzymes and cytokine/chemokine production in human whole blood. Inflammation 2015, 38(2), 858–70. [Google Scholar] [CrossRef] [PubMed]
  110. Ferriola, P.C.; Cody, V.; Middleton, E., Jr. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem Pharmacol 1989, 38(10), 1617–24. [Google Scholar] [CrossRef] [PubMed]
  111. Kondža, M.; Bojić, M.; Tomić, I.; Maleš, Ž.; Rezić, V.; Ćavar, I. Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids. Molecules 2021, 26(10), 3018. [Google Scholar] [CrossRef] [PubMed]
  112. Kondža, M.; Rimac, H.; Maleš, Ž.; Turčić, P.; Ćavar, I.; Bojić, M. Inhibitory Effect of Acacetin, Apigenin, Chrysin and Pinocembrin on Human Cytochrome P450 3A4. Croat Chem Acta 2020, 93(1), 33–39. [Google Scholar] [CrossRef]
  113. Cho, Y.A.; Choi, J.S.; Burm, J.P. Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. Pharmacol Rep 2011, 63(4), 1066–73. [Google Scholar] [CrossRef] [PubMed]
  114. Shimada, T.; Tanaka, K.; Takenaka, S.; Murayama, N.; Martin, M.V.; Foroozesh, M.K; Yamazaki, H.; Guengerich, F.P.; Komori, M. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem Res Toxicol 2010, 23(12), 1921–35. [Google Scholar] [CrossRef] [PubMed]
  115. Scott, L.M.; Durant, P.; Leone-Kabler, S.; Wood, C.E.; Register, T.C.; Townsend, A.; Cline, J.M. Effects of prior oral contraceptive use and soy isoflavonoids on estrogen-metabolizing cytochrome P450 enzymes. J Steroid Biochem Mol Biol 2008, 112(4-5), 179–85. [Google Scholar] [CrossRef] [PubMed]
  116. Šarić Mustapić, D.; Debeljak, Ž.; Maleš, Ž.; Bojić, M. The Inhibitory Effect of Flavonoid Aglycones on the Metabolic Activity of CYP3A4 Enzyme. Molecules 2018, 23(10), 2553. [Google Scholar] [CrossRef] [PubMed]
  117. Niwa, T.; Toyota, M.; Kawasaki, H.; Ishii, R.; Sasaki, S. Comparison of the Stimulatory and Inhibitory Effects of Steroid Hormones and α-Naphthoflavone on Steroid Hormone Hydroxylation Catalyzed by Human Cytochrome P450 3A Subfamilies. Biol Pharm Bull 2021, 44(4), 579–584. [Google Scholar] [CrossRef] [PubMed]
  118. Brahmi, Z.; Niwa, H.; Yamasato, M.; Shigeto, S.; Kusakari, Y.; Sugaya, K.; Onose, J.; Abe, N. Effective cytochrome P450 (CYP) inhibitor isolated from thyme (Thymus saturoides) purchased from a Japanese market. Biosci Biotechnol Biochem 2011, 75(11), 2237–9. [Google Scholar] [CrossRef] [PubMed]
  119. Meng, M.; Li, X.; Zhang, X.; Sun, B. Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4. Pharm Biol 2021, 59(1), 880–883. [Google Scholar] [CrossRef] [PubMed]
  120. Ho, P.C.; Saville, D.J.; Wanwimolruk, S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 2001, 4(3), 217–27. [Google Scholar]
  121. Li, Y.; Qin, J.; Wu, H.; Xu, Y.; Zhang, L.; Su, K.; Cui, Y.; Wang, H. In vitro inhibitory effect of lysionotin on the activity of cytochrome P450 enzymes. Pharm Biol 2020, 58(1), 695–700. [Google Scholar] [CrossRef]
  122. Han, Y.L.; Li, D.; Yang, Q.J.; Zhou, Z.Y.; Liu, L.Y.; Li, B.; Lu, J.; Guo, C. In vitro inhibitory effects of scutellarin on six human/rat cytochrome P450 enzymes and P-glycoprotein. Molecules 2014, 19(5), 5748–60. [Google Scholar] [CrossRef] [PubMed]
  123. Berginc, K.; Milisav, I.; Kristl, A. Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir. Drug Metab Pharmacokinet 2010, 25(6), 521–30. [Google Scholar] [CrossRef] [PubMed]
  124. Wei, S.; Ji, H.; Yang, B.; Ma, L.; Bei, Z.; Li, X.; Dang, H.; Yang, X.; Liu, C.; Wu, X.; Chen, J. Impact of chrysosplenetin on the pharmacokinetics and anti-malarial efficacy of artemisinin against Plasmodium berghei as well as in vitro CYP450 enzymatic activities in rat liver microsome. Malar J 2015, 14, 432. [Google Scholar] [CrossRef]
  125. Zhang, N.; Liu, J.; Chen, Z.; Dou, W. In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes. Pharm Biol 2019, 57(1), 571–576. [Google Scholar] [CrossRef]
  126. Liu, L.; Sun, S.; Rui, H.; Li, X. In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes. Pharm Biol 2017, 55(1), 1868–1874. [Google Scholar] [CrossRef] [PubMed]
  127. Zhang, Z.J.; Xia, Z.Y.; Wang, J.M.; Song, X.T.; Wie, J.F.; Kang, W.Y. Effects of Flavonoids in Lysimachia clethroides Duby on the Activities of Cytochrome P450 CYP2E1 and CYP3A4 in Rat Liver Microsomes. Molecules 2016, 21(6), 738. [Google Scholar] [CrossRef] [PubMed]
  128. Pilipenko, N.; Ropstad, E.; Halsne, R.; Zamaratskaia, G. Effect of Naringenin, Quercetin, and Sesamin on Xenobiotica-Metabolizing CYP1A and CYP3A in Mice Offspring after Maternal Exposure to Persistent Organic Pollutants. Biomed Res Int 2017, 2017, 8472312. [Google Scholar] [CrossRef]
  129. Alrushaid, S.; Zhao, Y.; Sayre, C.L.; Maayah, Z.H.; Forrest, M.L.; Senadheera, S.N.; Chaboyer, K.; Anderson, H.D.; El-Kadi, A.O.S.; Davies, N.M. Mechanistically elucidating the in vitro safety and efficacy of a novel doxorubicin derivative. Drug Deliv Transl Res 2017, 7(4), 582–597. [Google Scholar] [CrossRef] [PubMed]
  130. Ekstrand, B.; Rasmussen, M.K.; Woll, F.; Zlabek, V.; Zamaratskaia, G. In vitro gender-dependent inhibition of porcine cytochrome p450 activity by selected flavonoids and phenolic acids. Biomed Res Int 2015, 2015, 387918. [Google Scholar] [CrossRef]
  131. Yim, D.; Kim, M.J.; Shin, Y.; Lee, S.J.; Shin, J.G.; Kim, D.H. Inhibition of Cytochrome P450 Activities by Sophora flavescens Extract and Its Prenylated Flavonoids in Human Liver Microsomes. Evid Based Complement Alternat Med 2019, 2019, 2673769. [Google Scholar] [CrossRef]
  132. Song, H.; Wei, C.; Yang, W.; Niu, Z.; Gong, M.; Hu, H.; Wang, H. Alpinetin suppresses CYP3A4, 2C9, and 2E1 activity in vitro. Pharm Biol 2022, 60(1), 1032–1037. [Google Scholar] [CrossRef]
  133. Lu, W.J.; Ferlito, V.; Xu, C.; Flockhart, D.A.; Caccamese, S. Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms. Chirality 2011, 23(10), 891–6. [Google Scholar] [CrossRef] [PubMed]
  134. Satoh, T.; Fujisawa, H.; Nakamura, A.; Takahashi, N.; Watanabe, K. Inhibitory Effects of Eight Green Tea Catechins on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activities. J Pharm Pharm Sci 2016, 19(2), 188–97. [Google Scholar] [CrossRef]
  135. Albassam, A.A.; Markowitz, J.S. An Appraisal of Drug-Drug Interactions with Green Tea (Camellia sinensis). Planta Med 2017, 83(6), 496–508. [Google Scholar] [CrossRef]
  136. Misaka, S.; Kawabe, K.; Onoue, S.; Werba, J.P.; Giroli, M.; Tamaki, S.; Kan, T.; Kimura, J.; Watanabe, H.; Yamada, S. Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes. Drug Metab Pharmacokinet 2013, 28(3), 244–9. [Google Scholar] [CrossRef] [PubMed]
  137. Monostory, K.; Vereczkey, L.; Lévai, F.; Szatmári, I. Ipriflavone as an inhibitor of human cytochrome P450 enzymes. Br J Pharmacol 1998, 123(4), 605–10. [Google Scholar] [CrossRef] [PubMed]
  138. Im, Y.; Kim, Y.W.; Song, I.S.; Joo, J.; Shin, J.H.; Wu, Z.; Lee, H.S.; Park, K.H.; Liu, K.H. Effect of TSHAC on human cytochrome P450 activity, and transport mediated by P-glycoprotein. J Microbiol Biotechnol 2012, 22(12), 1659–64. [Google Scholar] [CrossRef] [PubMed]
  139. Li, G.; Simmler, C.; Chen, L.; Nikolić, D.; Chen, S.N.; Pauli, G.F.; van Breemen, R.B. Cytochrome P450 inhibition by three licorice species and fourteen licorice constituents. Eur J Pharm Sci 2017, 109, 182–190. [Google Scholar] [CrossRef]
Preprints 95971 g001
Figure 1. Hem structure formula .
Figure 1. Hem structure formula .
Preprints 95971 g001
Preprints 95971 g002
Figure 2. Types of CYP3A4 inhibition as presented in [62].
Figure 2. Types of CYP3A4 inhibition as presented in [62].
Preprints 95971 g002
Preprints 95971 g003
Figure 3. Flavonoid basic structure.
Figure 3. Flavonoid basic structure.
Preprints 95971 g003
Preprints 95971 g004
Figure 4. Basic structures of flavonoids subgroups.
Figure 4. Basic structures of flavonoids subgroups.
Preprints 95971 g004
Table 1. Nomenclature of CYP enzymes based on the similarity of the protein sequence.
Table 1. Nomenclature of CYP enzymes based on the similarity of the protein sequence.
classification name amino acid homogeneity
superfamily CYP -
family CYP3 ≥40%
subfamily CYP3A ≥55%
enzyme CYP3A4 ≥98%
Table 2. Selected drugs as CYP3A4 inhibitors.
Table 2. Selected drugs as CYP3A4 inhibitors.
drug reversible inhibitor mechanism of inhibition reference
amiodarone yes protein 66
amlodipine yes heme 67
boceprevir no heme 68
clarithromycin no heme 69
diclofenac yes protein 70
diltiazem yes heme 65
irinotecan no protein 71
levonorgestrel yes heme & protein 72
oleandomycin no heme 73
prazosin yes protein 74
ritonavir yes heme 74
sertralin yes protein 75
saquinavir yes protein 76
Table 3. Flavones as CYP3A4 inhibitors – IC50 values.
Table 3. Flavones as CYP3A4 inhibitors – IC50 values.
flavonoid substrate material IC50 (μM) potency [58] substituents REF
R3 R5 R6 R7 R8 R2’ R3’ R4’ R5’
2’-methoxy-5,7-dihydroxyflavone MDM CYP3A4 2 intermediate - OH - OH - OCH3 - - - 114
3’4’-dimethoxy-5,7-dihydroxyflavone MDM CYP3A4 6.5 intermediate - OH - OH - - OCH3 OCH3 - 114
3’-methoxy-5,7-dihydroxyflavone MDM CYP3A4 16 intermediate - OH - OH - - OCH3 - - 114
3-hydroxyflavone TST HLM 66.9 ± 4.0 weak OH - - - - - - - - 115
5-hydroxyflavone TST HLM 103.82 ± 0.98 weak - OH - - - - - - - 115
7-hydroxyflavone TST HLM 66.2 ± 5.8 weak - - - OH - - - - - 115
acacetin NFD CYP3A4 7.5 ± 2.7 intermediate - OH - OH - - - OCH3 - 111
acacetin TST CYP3A4 10.9 ± 0.3 intermediate 111
acacetin MDM CYP3A4 6.5 intermediate 114
acacetin TST CYP3A4 10.9 ± 0.3 intermediate 112
acacetin TST HLM 6.25 ± 0.96 intermediate 115
apigenin NFD CYP3A4 8.4 ± 1.1 intermediate - OH - OH - - - OH - 111
apigenin TST CYP3A4 11.4 ± 0.4 intermediate 111
apigenin MDM CYP3A4 2.3 ± 0.3 intermediate 114
apigenin TST CYP3A4 11.4 ± 0.4 intermediate 112
apigenin TST CYP3A4 30.8 ± 7.6 intermediate 118
apigenin TST HLM 1.47 ± 0.24 intermediate 115
baicalein BTC BAC 9.2 intermediate - OH OH OH - - - - - 113
baicalein TST RLM 12.03 intermediate 119
baicalein TST HLM 9.60 ± 1.18 intermediate 115
chrysin NFD CYP3A4 2.5 ± 0.6 intermediate - OH - OH - - - - - 111
chrysin TST CYP3A4 0.6 ± 0.5 strong 111
chrysin QIN HLM 70 weak 120
chrysin MDM CYP3A4 7.4 ± 1.1 intermediate 114
chrysin TST CYP3A4 0.6 ± 0.5 strong 112
chrysin TST CYP3A4 94.7 ± 30.9 weak 118
chrysin TST HLM 3.76 ± 1.13 intermediate 115
daidzein TST HLM >100 weak - - OH - - - - OH - 115
continued
diosmetin TST HLM 58.6 ± 26.5 intermediate - OH - OH - - OH OCH3 - 115
flavone QIN HLM 224 weak - - - - - - - - - 120
flavone TST HLM >100 weak 115
luteolin TST CYP3A4 57.7 ± 16.1 weak - OH - OH - - OH OH - 118
luteolin TST HLM 4.62 ± 1.26 intermediate 115
lysionotin TST HLM 13.85 intermediate - OH OCH3 OH OCH3 - - OCH3 - 121
nobiletin TST CYP3A4 20.6 ± 5.2 intermediate - OCH3 OCH3 OCH3 OCH3 - - OCH3 OCH3 118
scutellarin MDM HLM >100 weak - OH OH O-GRD - - - OH - 122
scutellarin MDM RLM >100 weak 122
α-naphthoflavone 2’-propargyl ether MDM CYP3A4 64 weak - - - benz. R8 benz. R7 PGE - - - 114
α-naphthoflavone 4’-propargyl ether MDM CYP3A4 55 weak - - - benz. R8 benz. R7 - - PGE - 114
α-naphtoflavone MDM CYP3A4 18 intermediate - - - benz. R8 benz. R7 - - - - 114
*BAC – baculosomes, benz.R7 and benz.R8 – benzene ring condensed on the position R7 – R8 , BTC - 7-benzyloxy-4-trifluoromethylcoumarine, HLM – human liver microsomes, MDM – midazolam, NFD – nifedipin, O-GRD – O-glucuronide, PGE – propargyl-ether, QIN – quinine, REF – reference , RLM – rat liver microsome, TST – testosterone.
Table 4. Flavones as CYP3A4 inhibitors – enzyme residual activity.
Table 4. Flavones as CYP3A4 inhibitors – enzyme residual activity.
flavonoid substrate material conc. (μM) CYP3A4 residual activity (%) substituents REF
R3 R5 R6 R7 R8 R2’ R3’ R4’ R5’
acacetin TST BAC 100 5 ± 4 - OH - OH - - - OCH3 - 116
apigenin TST BAC 100 24 ± 3 - OH - OH - - - OH - 116
apigenin QIN HLM 100 63.6 120
baicalein BTC BAC 10 50 - OH OH OH - - - - - 113
baicalein TST RLM 100 20 119
chrysin TST BAC 100 17 ± 3 - OH - OH - - - - - 116
chrysin QIN HLM 200 44.6 120
chrysin dimethylether TST BAC 100 61 ± 21 - OCH3 - OCH3 - - - - - 116
flavone QIN HLM 100 87.7 - - - - - - - - - 120
flavone QIN HLM 200 60.4 120
lysionotin TST HLM 100 13.67 - OH OCH3 OH OCH3 - - OCH3 - 121
nobiletin SAQM1 HLM 1 83.7 ± 4.1 - OCH3 OCH3 OCH3 OCH3 - - OCH3 OCH3 123
nobiletin SAQM3 HLM 1 85.2 ± 4.6 123
rutin SAQM1 HLM 1 81.7 ± 1.4 O-G-R OH - OH - - OH OH - 123
rutin SAQM3 HLM 1 83.0 ± 3.7 123
tangeretin TST BAC 1 42 ± 3 - OCH3 OCH3 OCH3 OCH3 - - OCH3 - 116
tangeretin SAQM1 HLM 1 89.0 ± 2.0 123
tangeretin SAQM3 HLM 1 85.3 ± 6.1 123
α-naphtoflavone TST HLM 100 6.8 - - - benz. R8 benz. R7 - - - - 117
*BAC – baculosomes, benz.R7 and benz.R8 – benzene ring condensed on the position R7 – R8, BTC - 7-benzyloxy-4-trifluoromethylcoumarine, conc. – concentration, HLM – human liver microsomes, O-G-R – O-glucose-rhamnose, QIN – quinine, REF – reference, RLM – rat liver microsome, SAQM1 – saquinavir (formation of M1 metabolite), SAQM3 – saquinavir (formation of M1 metabolite), TST – testosterone.
Table 5. Flavonols as CYP3A4 inhibitors – IC50 values.
Table 5. Flavonols as CYP3A4 inhibitors – IC50 values.
flavonoid substrate material IC50 (μM) potency [58] substituents REF
R3 R5 R6 R7 R2’ R3’ R4’ R5’ R5’
chrysosplenetin MDM RLM 3.38 intermediate - OH OCH3 OCH3 - OCH3 - - - 124
dihydromyricetin TST HLM 14.75 intermediate - OH - OH - OH OH OH - 126
fisetin QIN HLM 44 intermediate - - - OH - - OH OH - 120
fisetin TST CYP3A4 40.7 ± 7.4 intermediate 118
galangin QIN HLM 117 weak - OH - OH - - - - - 120
galangin MDM CYP3A4 2.3 intermediate 114
kaempferitrin TST HLM 13.87 intermediate R OH - O-R - - OH - - 125
kaempferol QIN HLM 223 weak - OH - OH - - OH - - 120
kaempferol TST CYP3A4 32.65 ± 1.32 intermediate 127
kaempferol TST CYP3A4 18.3 ± 5.3 intermediate 118
kaempferol TST HLM 6.51 ± 1.01 intermediate 115
morin QIN HLM 75.2 ± 8.7 weak - OH - OH OH - OH - - 115
myricetin TST HLM 10.7 ± 2.2 intermediate - OH - OH - OH OH OH - 115
quercetin TST CYP3A4 28.0 ± 5.2 intermediate - OH - OH - OH OH - - 127
quercetin TST CYP3A4 28.0 ± 5.2 intermediate 118
quercetin MDM RLM 27.1 intermediate 128
quercetin TST HLM 5.74 ± 1.16 intermediate 115
*HLM – human liver microsomes, RLM – rat liver microsomes , MDM – midazolam, QIN – quinine , R – rhamnoside, REF – reference, TST – testosterone.
Table 6. Flavonols as CYP3A4 inhibitors – enzyme residual activity.
Table 6. Flavonols as CYP3A4 inhibitors – enzyme residual activity.
flavonoid substrate material conc. (μM) CYP3A4 residual activity (%) substituents REF
R3 R5 R6 R7 R8 R2’ R3’ R4’ R5’
astragalin TST CYP3A4 5 93.35 G OH - OH - - - OH - 127
chrysosplenetin MDM RLM 50 18.27 ± 14.55 - OH OCH3 OCH3 - OCH3 - - - 124
dihydromyricetin TST HLM 100 18 - OH - OH - OH OH OH - 126
doxorubicine-quercetine conjugate QIN CYP3A4 100 50 - OH - OH - - OH D - 129
fisetin QIN HLM 100 27.5 - - - OH - - OH OH - 120
galangin QIN HLM 100 45.5 - OH - OH - - - - - 120
isoquercetin TST CYP3A4 5 83.32 G OH - OH - - OH OH - 127
isorahmetin TST BAC 100 73 ± 6 - OH - OH - - OCH3 OH - 116
isorahmetin BTC PLM 128 60 130
kaempferitrin TST HLM 100 18 R OH - O-R - - OH - - 125
kaempferol QIN HLM 100 58.6 - OH - OH - - OH - - 120
kaempferol TST CYP3A4 5 73.8 127
morin QIN HLM 188 65.6 - OH - OH OH - OH - - 120
myricetin QIN HLM 100 6.4 - OH - OH - OH OH OH - 120
myricetin BTC PLM 128 60 130
quercetin QIN HLM 100 35.1 - OH - OH - OH OH - - 120
quercetin TST CYP3A4 5 66.82 127
quercetin SAQ HLM 1 90.6 ± 0.5 123
*BAC – baculosomes, BTC - 7-benzyloxy-4-trifluoromethylcoumarine, conc. – concentration , D – doxorubicine, G – glucoside, HLM – human liver microsomes, MDM – midazolam, PLM – pig liver microsomes , QIN – quinine, R – rhamnoside , REF – reference, RLM – rat liver microsomes, SAQ – saquinavir, TST – testosterone.
Table 7. Flavanones as CYP3A4 inhibitors – IC50 values.
Table 7. Flavanones as CYP3A4 inhibitors – IC50 values.
flavonoid substrate material IC50 (μM) potency [58] substituents REF
R3 R5 R6 R7 R8 R2’ R3’ R4’ R5’ R6’
(R)-naringenin TST HLM 9.7 intermediate - OH - OH - - - OH - - 133
(S)-naringenin TST HLM 21.4 intermediate - OH - OH - - - OH - - 133
7-Hydroxyflavanone TST HLM 53.5 ± 7.2 weak - - - OH - - - - - 115
alpinetin TST HLM 8.23 intermediate - OCH3 - OH - - - - - 132
eriodictyol TST HLM 65.2 ± 8.0 weak - OH - OH - - OH OH - - 115
flavanone TST HLM 101 ± 15 weak - - - - - - - - - - 115
hesperetin QIN HLM 163 weak - OH - OH - - - OCH3 OH - 120
hesperetin TST HLM 61.8 ± 1.3 weak 115
hesperidin QIN HLM 601 weak - OH - O-G-R - - OH OCH3 - - 120
kushenol A MDM HLM >50 weak - OH - OH MPH - - - - OH 131
kushenol C MDM HLM 3.95 intermediate - OH - OH MPH OH - OH - - 131
kushebol I MDM HLM 0.57 strong OH OCH3 - OH MPH OH - OH - - 131
kushenol M MDM HLM 1.29 intermediate OH OH MP OH MPH OH - OH - - 131
leachianone A MDM HLM 0.69 strong - OH OH MPH - - OH - OCH3 131
naringenin MDM RLM 40.3 intermediate - OH - OH - - - OH - - 128
naringenin QIN HLM 139 weak 120
naringenin TST HLM 17.6 intermediate 133
naringenin TST HLM 6.50 ± 1.54 intermediate 115
naringin QIN HLM 1349 weak - OH O-R-G - - - OH - - 120
neohesperidin QIN HLM 280 weak - OH O-R-G - - OH OCH3 - - 120
pinocembrin NIF CYP3A4 4.3 ± 1.1 intermediate - OH - OH - - - - - - 111
pinocembrin TST CYP3A4 5.0 ± 0.6 intermediate 111
pinocembrin TST CYP3A4 5.0 ± 0.6 intermediate 112
pinocembrin TST HLM 28.6 ± 6.1 intermediate 115
sophoraflavone G MDM HLM 0.78 strong - OH - O-G - - - OH - - 131
*G – glucose, HLM – human liver microsomes, MDM – midazolam, MP – 2-methypent-2-ene, MPH - (2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl, NIF – nifedipine , O-R-G – O-rhamnose-glucose, QIN – quinine, R – rhamnose, REF – reference, RLM – rat liver microsomes, TST – testosterone.
Table 8. Flavanones as CYP3A4 inhibitors – enzyme residual activity.
Table 8. Flavanones as CYP3A4 inhibitors – enzyme residual activity.
flavonoid substrate material conc. (μM) CYP3A4 residual activity (%) substituents REF
R3 R5 R6 R7 R8 R2’ R3’ R4’ R5’ R6’
alpinetin TST HLM 100 20 - OCH3 - OH - - - - - 132
hesperetin QIN HLM 100 64.5 - OH - OH - - - OCH3 OH - 120
hesperidin QIN HLM 100 79.6 - OH - O-G-R - - OH OCH3 - - 120
naringenin QIN HLM 100 60.9 - OH - OH - - - OH - - 120
naringenin SAQ HLM 1 77.0 ± 1.1 123
naringin QIN HLM 100 51.1 - OH O-R-G - - - OH - - 120
naringin SAQ HLM 1 76.7 ± 0.3 123
neohesperidin QIN HLM 200 61.7 - OH O-R-G - - OH OCH3 - - 120
pinocembrin TST BAC 100 50 ± 15 - OH - OH - - - - - - 116
prunin QIN HLM 100 73.9 OH O-G OH 120
*BAC – baculosomes, G – glucose, HLM – human liver microsomes, QIN – quinine, REF – reference, conc. – concentration, RLM – rat liver microsomes, SAQ – saquinavir, TST – testosterone.
Table 9. Other flavonoids as CYP3A4 inhibitors – IC50 values.
Table 9. Other flavonoids as CYP3A4 inhibitors – IC50 values.
flavonoid substrate material IC50 (μM) potency [58] substituents REF
R2 R3 R4 R5 R6 R7 R8 R3’ R4’ R5’
FLAVANONOLS
taxifolin TST HLM 68.9 ± 2.3 weak - - - OH - OH - - - - 115
FLAVANOLS (CATECHINS)
(-)-catechin-3-O-gallate MDM HLM 71.5 ± 7.51 weak - GA - OH - OH - - OH OH 134
(-)-epigallocatechin-3-gallate MDM BAC 41 intermediate - GA - OH - OH - OH OH OH 135
(-)-epigallocatechin-3-gallate MDM HLM 23 intermediate 135
(-)-epigallocatechin-3-gallate MDM HLM 23.3 intermediate 136
(-)-epigallocatechin-3-O-gallate MDM HLM 23.7 ± 1.54 intermediate - O-GA - OH - OH - OH OH OH 134
(-)-epigallocatechin-3-O-gallate MDM HLM 40.8 ± 6.93 intermediate 134
ISOFLAVONOIDS
7-hydroxy-isoflavone NIF HLM 129.5 ± 12.49 weak - - - - - OH - - - - 137
8-methoxycirsilineol TST CYP3A4 1.71 ± 0.3 intermediate - - OH OCH3 OCH3 OCH3 OH - - OCH3 118
genistein TST HLM >100 weak - - - OH - OH - - OH - 115
CHALCONES
TSAHC MDM HLM >20 intermediate - - OH - - - - - TSA - 138
licochalcone A MDM HLM 47.4 intermediate OCH3 OH MBE OH 139
*BAC – baculosomes, GA – gallic acid, HLM – human liver microsomes, MBE – 2-methylbut-3-en-2-yl, MDM – midazolam, NIF – nifedipine, REF – reference, TSA - 4'-p-toluenesulfonylamide, TSAHC - 4'-(p-toluenesulfonylamido)-4-hydroxychalcone, TST – testosterone.
Table 10. Other flavonoids as CYP3A4 inhibitors – enzyme residual activity.
Table 10. Other flavonoids as CYP3A4 inhibitors – enzyme residual activity.
flavonoid substrate material conc. (μM) CYP3A4 residual activity (%) substituents REF
R2 R3 R4 R5 R6 R7 R8 R3’ R4’ R5’
FLAVANOLS (CATECHINS)
(-)-epicatechin IRT HLM 100 53 - OH - OH - OH - - OH OH 135
(-)-epigallocatechin-3-gallate IRT HLM 100 53 - GA - OH - OH - OH OH OH 135
ISOFLAVONOIDS
7-hydroxy-isoflavone NIF HLM 100 75 - - - - - OH - - - - 137
CHALCONES
N9 MDM HLM 100 75 - OCH3 - - OCH3 - - pyr.R4’ pyr.R3’ - 138
*conc. – concentration, GA – gallic acid, HLM – human liver microsomes, IRT – irinotecan, MDM – midazolam, N9 - (2E)-1-(2,5-dimethoxyphenyl)-3-(6-quinoxalinyl)-2-propen-1-one, NIF – nifedipine, pyr. R4’ and pyr. R3’ – pyrazine ring condensed on the position R4’ – R3’, REF – reference.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated